DaRT Seeds for Brain Cancer

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Alpha Tau Medical LTD.

No Placebo Group

Trial Summary

What is the purpose of this trial?

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

Eligibility Criteria

This trial is for individuals with recurrent glioblastoma, a type of brain cancer. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and have no conflicting conditions.

Inclusion Criteria

Measurable disease per RANO criteria

Estimated life expectancy more than 6 months

Adequate blood counts and blood chemistry levels at initial screening

Exclusion Criteria

I have a condition that makes me bleed easily.

Pregnancy or lactation

Prior allergic reaction to the study drugs

Treatment Details

Interventions

• DaRT seeds (Brachytherapy)

Trial Overview The study is testing the safety and feasibility of a device called DaRT seeds that emit alpha radiation directly into the tumor in patients with recurrent glioblastoma.

Participant Groups

Group I: Experimental: DaRT seeds Experimental Treatment 1 Intervention

DaRT sources are inserted into the tumor according to a pre determined plan. The delivery of the DaRT Sources into the tumor is done by using a designated Alpha DaRT Applicator .

Who Is Running the Clinical Trial?

Alpha Tau Medical LTD.

Lead Sponsor

Trials

28

Recruited

920+